Influence of cefizoxime alapivoxil on intestinal bacterial flora: A study in gnotibiotic mice inoculated with 4 bacterial strains

Satoshi Iwata, Yashitake Sato, Hironobu Akita, Keisuke Sunakawa, Intetsu Kobayashi, Hiroko Tokuoka, Kazuo Yano, Shinya Yamaji

Research output: Contribution to journalArticle

Abstract

We studied the influence of ceftizoxime alapivoxil (CZX-AP), a new prodrug oral cephem agent, on intestinal bacterial flora in gnotobiotic mice inoculated with 4 bacterial strains. We administered 20 mg/kg of CZX-AP once daily for 5 consecutive days to mice inoculated with bacterial strains, Escherichia coli Hokken M, Enterococcus facealis Hokken M, Bacteroides fragilis GKP 0001 and Bifidobacterium breve YIT 4006. We found a decrease in E. coli, but no change in the other 3 bacteria. We also found a decrease in the number of viable E. coli in the contents of each part of the digestive tract (stomach, upper intestine, middle intestine, lower intestine, colon) 4 hours after the last dose was administered, but no change in the other 3 bacteria. This agrees with results we found on changes in the number of fecal flora. All specimens from the stool or digestive tract contents tested for β-lactamase activity before and after drug administration were positive. The minimum inhibitory concentration (MIC) of ceftizoxime (CZX), the active moiety of CZX-AP we used, with inoculum size of 106CFU/mL, was 0.005 μg/mL for E. coli, 12.5 μg/mL for E. facealis, 3.13 μg/mL for B. fragilis and 12.5 μg/mL for B. breve. We found no MIC increase concomitant to drug administration for any bacterial strains.

Original languageEnglish
Pages (from-to)323-328
Number of pages6
JournalJapanese Journal of Chemotherapy
Volume50
Issue number6
Publication statusPublished - 2002
Externally publishedYes

Fingerprint

Escherichia coli
Intestines
Bacteroides fragilis
Microbial Sensitivity Tests
Ceftizoxime
Germ-Free Life
Bacteria
Gastrointestinal Contents
Enterococcus
Prodrugs
Pharmaceutical Preparations
Gastrointestinal Tract
Stomach
Colon
Gastrointestinal Microbiome
ceftizoxime alapivoxil
Bifidobacterium breve

Keywords

  • Ceftizoxime alapivoxil
  • Gnotobiote

ASJC Scopus subject areas

  • Pharmacology

Cite this

Iwata, S., Sato, Y., Akita, H., Sunakawa, K., Kobayashi, I., Tokuoka, H., ... Yamaji, S. (2002). Influence of cefizoxime alapivoxil on intestinal bacterial flora: A study in gnotibiotic mice inoculated with 4 bacterial strains. Japanese Journal of Chemotherapy, 50(6), 323-328.

Influence of cefizoxime alapivoxil on intestinal bacterial flora : A study in gnotibiotic mice inoculated with 4 bacterial strains. / Iwata, Satoshi; Sato, Yashitake; Akita, Hironobu; Sunakawa, Keisuke; Kobayashi, Intetsu; Tokuoka, Hiroko; Yano, Kazuo; Yamaji, Shinya.

In: Japanese Journal of Chemotherapy, Vol. 50, No. 6, 2002, p. 323-328.

Research output: Contribution to journalArticle

Iwata, S, Sato, Y, Akita, H, Sunakawa, K, Kobayashi, I, Tokuoka, H, Yano, K & Yamaji, S 2002, 'Influence of cefizoxime alapivoxil on intestinal bacterial flora: A study in gnotibiotic mice inoculated with 4 bacterial strains', Japanese Journal of Chemotherapy, vol. 50, no. 6, pp. 323-328.
Iwata, Satoshi ; Sato, Yashitake ; Akita, Hironobu ; Sunakawa, Keisuke ; Kobayashi, Intetsu ; Tokuoka, Hiroko ; Yano, Kazuo ; Yamaji, Shinya. / Influence of cefizoxime alapivoxil on intestinal bacterial flora : A study in gnotibiotic mice inoculated with 4 bacterial strains. In: Japanese Journal of Chemotherapy. 2002 ; Vol. 50, No. 6. pp. 323-328.
@article{557ad00f804346e4957efab11b0b711b,
title = "Influence of cefizoxime alapivoxil on intestinal bacterial flora: A study in gnotibiotic mice inoculated with 4 bacterial strains",
abstract = "We studied the influence of ceftizoxime alapivoxil (CZX-AP), a new prodrug oral cephem agent, on intestinal bacterial flora in gnotobiotic mice inoculated with 4 bacterial strains. We administered 20 mg/kg of CZX-AP once daily for 5 consecutive days to mice inoculated with bacterial strains, Escherichia coli Hokken M, Enterococcus facealis Hokken M, Bacteroides fragilis GKP 0001 and Bifidobacterium breve YIT 4006. We found a decrease in E. coli, but no change in the other 3 bacteria. We also found a decrease in the number of viable E. coli in the contents of each part of the digestive tract (stomach, upper intestine, middle intestine, lower intestine, colon) 4 hours after the last dose was administered, but no change in the other 3 bacteria. This agrees with results we found on changes in the number of fecal flora. All specimens from the stool or digestive tract contents tested for β-lactamase activity before and after drug administration were positive. The minimum inhibitory concentration (MIC) of ceftizoxime (CZX), the active moiety of CZX-AP we used, with inoculum size of 106CFU/mL, was 0.005 μg/mL for E. coli, 12.5 μg/mL for E. facealis, 3.13 μg/mL for B. fragilis and 12.5 μg/mL for B. breve. We found no MIC increase concomitant to drug administration for any bacterial strains.",
keywords = "Ceftizoxime alapivoxil, Gnotobiote",
author = "Satoshi Iwata and Yashitake Sato and Hironobu Akita and Keisuke Sunakawa and Intetsu Kobayashi and Hiroko Tokuoka and Kazuo Yano and Shinya Yamaji",
year = "2002",
language = "English",
volume = "50",
pages = "323--328",
journal = "Japanese Journal of Chemotherapy",
issn = "1340-7007",
publisher = "Japan Society of Chemotherapy",
number = "6",

}

TY - JOUR

T1 - Influence of cefizoxime alapivoxil on intestinal bacterial flora

T2 - A study in gnotibiotic mice inoculated with 4 bacterial strains

AU - Iwata, Satoshi

AU - Sato, Yashitake

AU - Akita, Hironobu

AU - Sunakawa, Keisuke

AU - Kobayashi, Intetsu

AU - Tokuoka, Hiroko

AU - Yano, Kazuo

AU - Yamaji, Shinya

PY - 2002

Y1 - 2002

N2 - We studied the influence of ceftizoxime alapivoxil (CZX-AP), a new prodrug oral cephem agent, on intestinal bacterial flora in gnotobiotic mice inoculated with 4 bacterial strains. We administered 20 mg/kg of CZX-AP once daily for 5 consecutive days to mice inoculated with bacterial strains, Escherichia coli Hokken M, Enterococcus facealis Hokken M, Bacteroides fragilis GKP 0001 and Bifidobacterium breve YIT 4006. We found a decrease in E. coli, but no change in the other 3 bacteria. We also found a decrease in the number of viable E. coli in the contents of each part of the digestive tract (stomach, upper intestine, middle intestine, lower intestine, colon) 4 hours after the last dose was administered, but no change in the other 3 bacteria. This agrees with results we found on changes in the number of fecal flora. All specimens from the stool or digestive tract contents tested for β-lactamase activity before and after drug administration were positive. The minimum inhibitory concentration (MIC) of ceftizoxime (CZX), the active moiety of CZX-AP we used, with inoculum size of 106CFU/mL, was 0.005 μg/mL for E. coli, 12.5 μg/mL for E. facealis, 3.13 μg/mL for B. fragilis and 12.5 μg/mL for B. breve. We found no MIC increase concomitant to drug administration for any bacterial strains.

AB - We studied the influence of ceftizoxime alapivoxil (CZX-AP), a new prodrug oral cephem agent, on intestinal bacterial flora in gnotobiotic mice inoculated with 4 bacterial strains. We administered 20 mg/kg of CZX-AP once daily for 5 consecutive days to mice inoculated with bacterial strains, Escherichia coli Hokken M, Enterococcus facealis Hokken M, Bacteroides fragilis GKP 0001 and Bifidobacterium breve YIT 4006. We found a decrease in E. coli, but no change in the other 3 bacteria. We also found a decrease in the number of viable E. coli in the contents of each part of the digestive tract (stomach, upper intestine, middle intestine, lower intestine, colon) 4 hours after the last dose was administered, but no change in the other 3 bacteria. This agrees with results we found on changes in the number of fecal flora. All specimens from the stool or digestive tract contents tested for β-lactamase activity before and after drug administration were positive. The minimum inhibitory concentration (MIC) of ceftizoxime (CZX), the active moiety of CZX-AP we used, with inoculum size of 106CFU/mL, was 0.005 μg/mL for E. coli, 12.5 μg/mL for E. facealis, 3.13 μg/mL for B. fragilis and 12.5 μg/mL for B. breve. We found no MIC increase concomitant to drug administration for any bacterial strains.

KW - Ceftizoxime alapivoxil

KW - Gnotobiote

UR - http://www.scopus.com/inward/record.url?scp=0036323528&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036323528&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0036323528

VL - 50

SP - 323

EP - 328

JO - Japanese Journal of Chemotherapy

JF - Japanese Journal of Chemotherapy

SN - 1340-7007

IS - 6

ER -